Skip to main content
SpringerLink
Log in

Eindrücke von der Jahrestagung der amerikanischen Hämatologen

59. Jahrestagung der American Society of Hematology 2017

  • Aktuelles
  • Published:
Forum Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Seymour JF et al (2017) LBA-2 Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia – Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study. Presented at the 59th American Society of Hematology (ASH) Annual Meeting. December 9-12, 2017; Atlanta, GA. Abstract LBA-2. https://ash.confex.com/ash/2017/webprogram/Paper109076.html

  2. Hillmen P et al (2017) Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy. Presented at the 59th American Society of Hematology (ASH) Annual Meeting. Session: 642. CLL: Therapy, excluding Transplantation: Targeting MRD Negative CLL Through Combinations of Novel Agents and Antibody. https://ash.confex.com/ash/2017/webprogram/Paper104020.html

  3. Connors JM et al (2017) Brentuximab Vedotin Plus Doxorubicin, Vinblastine, Dacarbazine (A+AVD) As Frontline Therapy Demonstrates Superior Modified Progression-Free Survival Versus ABVD in Patients with Previously Untreated Stage III or IV Hodgkin Lymphoma (HL): The Phase 3 Echelon-1 Study. ASH 6: https://ash.confex.com/ash/2017/webprogram/Paper105589.html

  4. Mateos MV et al (2017) Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE). ASH: https://ash.confex.com/ash/2017/webprogram/Paper109143.html

  5. Neelapu SS et al (2017) Long-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). ASH: https://ash.confex.com/ash/2017/webprogram/Paper99983.html

  6. Neelapu SS et al (2017) Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 377(28):2531–2544. https://doi.org/10.1056/NEJMoa1707447

    Article  PubMed  Google Scholar 

  7. Schuster SJ et al (2017) Primary Analysis of Juliet: A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. ASH: https://ash.confex.com/ash/2017/webprogram/Paper105399.html

  8. Berdeja J, Kochenderfer JN et al (2017) Durable clinical responses in heavily pretreated patients with relapsed/refractory multiple myeloma: Updated results from a multicenter study of bb2121 anti-BCMA CAR T cell therapy. ASH: https://ash.confex.com/ash/2017/webprogram/Paper107984.htm

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eindrücke von der Jahrestagung der amerikanischen Hämatologen. Forum 33, 80–84 (2018). https://doi.org/10.1007/s12312-018-0392-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12312-018-0392-5

Search

Navigation